June 10, 2019
Chris Boshoff, Chief Development Officer, Pfizer Oncology While facing an uphill I/O battle with Bavencio (avelumab), which generated only 1% of what stalwart Keytruda (pembrolizumab) brought in during the first quarter of 2019, Pfizer continues to charge ahead with its...read more